Commonwealth Equity Services
PYXS icon

Commonwealth Equity Services’s Pyxis Oncology PYXS Stock Holding History

Commonwealth Equity Services’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Buy
42,455
+7,700
+22% +$14.7K ﹤0.01% 4222
2026
Q1 		$50.7K Sell
34,755
-5,000
-13% -$7.54K ﹤0.01% 4200
2025
Q4 		$45.7K Sell
39,755
-21,400
-35% -$75.5K ﹤0.01% 4189
2025
Q3 		$136K Hold
61,155
– – ﹤0.01% 4034
2025
Q2 		$67K Buy
61,155
+17,905
+41% +$20.2K ﹤0.01% 4128
2025
Q1 		$42K Buy
43,250
+17,000
+65% +$22.7K ﹤0.01% 4084
2024
Q4 		$41K Buy
26,250
+10,000
+62% +$28.8K ﹤0.01% 3998
2024
Q3 		$60K Hold
16,250
– – ﹤0.01% 3914
2024
Q2 		$54K Sell
16,250
-14,000
-46% -$58.9K ﹤0.01% 3886
2024
Q1 		$129K Buy
30,250
+17,300
+134% +$72.8K ﹤0.01% 3755
2023
Q4 		$23K Hold
12,950
– – ﹤0.01% 3810
2023
Q3 		$26K Buy
+12,950
New +$30K ﹤0.01% 3715

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Commonwealth Equity Services's PYXS Position: Q2 2026 in Review

Commonwealth Equity Services increased its Pyxis Oncology (PYXS) stake by 22% in Q2 2026, buying an estimated $14.7K and bringing the position to 42,455 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #4222.

Commonwealth Equity Services first reported a position in PYXS in Q3 2023 and has held it in 12 quarters since. The position peaked at $136K in Q3 2025. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Commonwealth Equity Services held 42,455 shares of Pyxis Oncology worth $128K as of Q2 2026.
  • Commonwealth Equity Services bought 7,700 Pyxis Oncology shares in Q2 2026, an estimated $14.7K.
  • Pyxis Oncology made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4222 holding.
  • Commonwealth Equity Services first reported a position in Pyxis Oncology in Q3 2023 and has held it in 12 quarters since.
  • Commonwealth Equity Services's Pyxis Oncology position peaked at $136K in Q3 2025.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.